The consensus for "event-free survival" (EFS) in bladder-sparing trials is now highly inclusive, counting even high-grade superficial (non-muscle invasive) relapses as events. This is a deliberately conservative choice to maximize patient safety and preempt the risk of these relapses leading to metastasis.

Data from the BART trial revealed that post-operative patients who experienced a locoregional relapse had a median survival of only 6.5-7 months. This grim prognosis was surprisingly identical to that of patients with distant metastasis, underscoring the critical importance of preventing local disease recurrence.

While bladder preservation is a key goal, there is an unavoidable risk. Forgoing definitive local treatment like surgery means a subset of patients will not be cured by systemic therapy alone and will miss their opportunity for a potentially curative operation, a crucial ethical consideration.

Despite initial concerns about irradiating the post-cystectomy bed due to bowel proximity, the BART trial demonstrated that using strict Intensity-Modulated Radiation Therapy (IMRT) makes the procedure safe. This approach resulted in only 17-20% grade two acute side effects, a reasonable trade-off for the clinical benefit.

As oncology moves toward bladder-sparing approaches, even highly effective systemic therapies won't be enough. To prevent local relapse and truly avoid cystectomy, a bladder-directed component, such as an intravesical therapy, will be a necessary part of the long-term treatment strategy.

While new systemic agents dominate MIBC discussions, chemo-radiation remains a critical treatment, especially for patients unsuitable for radical cystectomy due to age or comorbidities. For these individuals, it offers a potentially curative, bladder-preserving alternative that avoids the high risks and sequelae of major surgery.

Clinical experience suggests that CSCC recurring within or at the edge of a prior radiation field tends to exhibit more aggressive biological behavior. This context is a critical factor when assessing risk and deciding on subsequent treatment, such as adjuvant systemic therapy, even if other features seem borderline.

For bladder cancer patients with limited metastatic sites (oligometastatic disease) who respond well to systemic therapy, adding consolidative radiation like SBRT is a reasonable and well-tolerated strategy. This approach, supported by retrospective data and precedent in other cancers like prostate and kidney, aims to improve long-term disease control.

The rationale for the BART trial was the premise that locoregional relapses after cystectomy are a significant and often overlooked issue. While distant metastases get more attention, a substantial portion of treatment failures are local, causing significant morbidity and contributing to the 40% mortality rate at 2-3 years.